Jet Airways has currently postponed its plans to fly to the US till next year as the lawsuit filed by its US-based namesake airlines has been referred to the home ministry in India by the US department of transportation.

The airline has already used all its long-haul aircraft to service the India-London sector. Mr Carl Saldanha, chief financial officer, Jet Airways said, "The conflict with US-based Jet Airways will in all probabilities be resolved in our favour very soon but the other pressing reason behind not being able to fly immediately to the US is that we need more long haul aircraft. We are already plying our long-haul aircraft to London as we have recently introduced a new flight on that circuit. So we need more long-haul aircraft before we think of plying on the Indo-US circuit."

Jet Airways executive director Saroj K. Dutta, refusing to comment on the same, said, "The situation is status quo as of now." Earlier, before the serious allegations were levelled against the airline in the US, it had planned to launch its flights from Mumbai to New Jersey via Brussels from the third week of June, 2005. The US-based airline had alleged that Jet Airways had terrorist links. Jet Airways had instructed its American lawyers to take legal action against the president and chief executive officer of the US-based Jet Airways and denied all allegations, and said that the American company was attempting to besmirch its name.

In order to consolidate its already existing dominant presence in the Russian pharmaceutical market, pharma company J.B. Chemicals & Pharmaceuticals Ltd (JBCPL) is planning to set up a wholly owned subsidiary in Moscow. The subsidiary company called "OOO Unique Pharmaceuticals Laboratories" has been mandated to expand the company’s international business in Russia and CIS countries which has been its key growth driver in recent times. It will initiate its business plans with a start-up investment of $3 million.

Mr D.B. Mody, director of JBCPL, said, "We plan to grow our market share in the $5.5 billion (at retail price) pharma market in Russia and CIS countries and maintain our leadership position with introduction of new products and novel technologies in much wider therapeutic fields in near future." The bulk of the revenues (45 per cent) for JBCPL are in the form of export revenues generated mostly from these markets. In fiscal 2004-05, the total exports of JBCPL were pegged around Rs 211 crores at a total turnover of Rs 370 crores.

Elaborating on the Russian operations, Mr Mody added that the company, in the mid 90s forayed into Russia and was then amongst the first Indian companies to establish a representative office in Moscow. Currently, it has two marketing offices in Moscow and Kiev and operates in ten countries in CIS.